Description: Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
Home Page: www.chimerix.com
2505 Meridian Parkway
Durham,
NC
27713
United States
Phone:
919 806 1074
Officers
| Name | Title |
|---|---|
| Mr. Michael T. Andriole M.B.A. | CEO, President & Director |
| Dr. Michael A. Alrutz J.D., Ph.D. | Senior VP, General Counsel & Corporate Secretary |
| Dr. Allen S. Melemed M.B.A., M.D. | Chief Medical Officer |
| Ms. Michelle LaSpaluto | Chief Financial Officer |
| Mr. Thomas J. Riga | Chief Operating & Commercial Officer |
| Mr. David Jakeman CPA | Vice President of Accounting & Finance |
| Dr. Joshua E. Allen Ph.D. | Chief Scientific Officer |
| Dr. Roy W. Ware M.B.A., Ph.D. | Chief Manufacturing Technology Officer |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 1.1755 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5546 |
| Price-to-Sales TTM: | 462.7519 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 72 |